PROBIOTIX HEALTH LS-05 (X90) - Net Assets
Based on the latest financial reports, PROBIOTIX HEALTH LS-05 (X90) has net assets worth €1.79 Million EUR (≈ $2.09 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.38 Million ≈ $2.78 Million USD) and total liabilities (€591.00K ≈ $690.94K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read how much debt does PROBIOTIX HEALTH LS-05 carry for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.79 Million |
| % of Total Assets | 75.17% |
| Annual Growth Rate | -1.72% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 24.36 |
PROBIOTIX HEALTH LS-05 - Net Assets Trend (2022–2024)
This chart illustrates how PROBIOTIX HEALTH LS-05's net assets have evolved over time, based on quarterly financial data. Also explore X90 total asset value for the complete picture of this company's asset base.
Annual Net Assets for PROBIOTIX HEALTH LS-05 (2022–2024)
The table below shows the annual net assets of PROBIOTIX HEALTH LS-05 from 2022 to 2024. For live valuation and market cap data, see how much is PROBIOTIX HEALTH LS-05 worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.92 Million ≈ $2.25 Million |
+25.60% |
| 2023-12-31 | €1.53 Million ≈ $1.79 Million |
-23.11% |
| 2022-12-31 | €1.99 Million ≈ $2.33 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PROBIOTIX HEALTH LS-05's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 159548144.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €3.71 Million | 192.88% |
| Total Equity | €1.92 Million | 100.00% |
PROBIOTIX HEALTH LS-05 Competitors by Market Cap
The table below lists competitors of PROBIOTIX HEALTH LS-05 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Paranapanema S.A
SA:PMAM3
|
$13.13 Million |
|
Ralco Corporation Bhd
KLSE:7498
|
$13.14 Million |
|
Inocycle Technology Tbk PT
JK:INOV
|
$13.14 Million |
|
Peak Processing Limited
AU:PKP
|
$13.14 Million |
|
Citatah Tbk
JK:CTTH
|
$13.13 Million |
|
NFL Biosciences SAS
PA:ALNFL
|
$13.13 Million |
|
Winamp Group SA
PA:ALPET
|
$13.13 Million |
|
NPK Co.Ltd
KQ:048830
|
$13.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PROBIOTIX HEALTH LS-05's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,531,000 to 1,923,000, a change of 392,000 (25.6%).
- Net loss of 847,000 reduced equity.
- New share issuances of 1,214,000 increased equity.
- Other factors increased equity by 25,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-847.00K | -44.05% |
| Share Issuances | €1.21 Million | +63.13% |
| Other Changes | €25.00K | +1.3% |
| Total Change | €- | 25.60% |
Book Value vs Market Value Analysis
This analysis compares PROBIOTIX HEALTH LS-05's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.84x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 4.34x to 5.84x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | €0.02 | €0.07 | x |
| 2023-12-31 | €0.01 | €0.07 | x |
| 2024-12-31 | €0.01 | €0.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PROBIOTIX HEALTH LS-05 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -44.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -44.98%
- • Asset Turnover: 0.86x
- • Equity Multiplier: 1.13x
- Recent ROE (-44.05%) is above the historical average (-46.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | -48.79% | -44.65% | 0.77x | 1.42x | €-900.10K |
| 2024 | -44.05% | -44.98% | 0.86x | 1.13x | €-1.04 Million |
Industry Comparison
This section compares PROBIOTIX HEALTH LS-05's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $355,224,390
- Average return on equity (ROE) among peers: -60.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PROBIOTIX HEALTH LS-05 (X90) | €1.79 Million | -48.79% | 0.33x | $13.13 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $289.79 Million | -81.80% | 0.17x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $205.51 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $1.36 Billion | -38.77% | 0.36x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $-852.32K | 0.00% | 0.00x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $1.38 Billion | -51.05% | 0.17x | $1.82 Billion |
| BioNTech SE (22UA) | $267.00 Million | -17.98% | 1.45x | $20.05 Billion |
About PROBIOTIX HEALTH LS-05
ProBiotix Health Plc develops probiotics to tackle cardiovascular disease and other lifestyle conditions in the United Kingdom, the United States, and internationally. The company offers YourBiotixMH for menopause health; YourBiotixCH InstaMelt and YourBiotixCH for cholesterol maintenance; and YourBiotixX3 for cholesterol reduction. It also provides YourBiotixBP for blood pressure reduction; and … Read more